AV Darunavir
| PHA antivirals by mechanism |
drug: darunavir comb: cobicistat
32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients
32479865 2020. Lack of antiviral activity of darunavir against SARS-CoV-2.
32671131 2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32856282 2020. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.
32882767 2020. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
33221868 2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
C7337805 ?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.
32292805 2020. Data on the stability of darunavir/cobicistat suspension after tablet manipulation.
31676833 2019. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms.
32855991 2020. Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19".
| 32297571 2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus |
